Last reviewed · How we verify
Disitamab vedotin (disitamab-vedotin)
Disitamab vedotin is a marketed drug by Pfizer Inc. for the treatment of HER2-positive cancers. It is an antibody-drug conjugate that targets human epidermal growth factor receptor 2 (HER2). The drug comprises a humanized monoclonal antibody against HER2 conjugated to the cytotoxic agent monomethyl auristatin E (MMAE). Disitamab vedotin is indicated for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and locally advanced or metastatic esophageal squamous cell carcinoma. It has 100 trials and 136 publications. The commercial significance of disitamab vedotin is its ability to target HER2-positive cancers. Pfizer Inc. is the company behind this marketed drug.
At a glance
| Generic name | disitamab-vedotin |
|---|---|
| Sponsor | Pfizer |
| Drug class | antibody-drug conjugate |
| Target | human epidermal growth factor receptor 2 (HER2) |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Locally advanced or metastatic esophageal squamous cell carcinoma
Common side effects
Drug interactions
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- Live vaccines
- Other anticancer agents
Key clinical trials
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (PHASE3)
- A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (PHASE2)
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (PHASE2)
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial (PHASE2)
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab vedotin CI brief — competitive landscape report
- Disitamab vedotin updates RSS · CI watch RSS
- Pfizer portfolio CI